HC Wainwright & Co. reiterates Buy rating on Arrowhead Pharma, $120 price target

The FDA launched a Rare Disease Framework Initiative to boost drug development for rare diseases. Arrowhead Pharmaceuticals reported a 73% decrease in tau protein in a Phase 1/2a study of ARO-MAPT. First Tracks Biotherapeutics announced positive Phase 1b results for ANB033 in celiac disease. BioNTech's BNT113 missed its first primary endpoint in a head and neck cancer trial. GSK plans to cut over 1,000 jobs at a Belgium site.

Arrowhead Pharmaceuticals' ARO-MAPT showed significant tau protein reduction in a Phase 1/2a study, with up to 85% reduction at high doses. Analysts view the data favorably, suggesting a potential competitive edge over Biogen's diranersen. The trial is ongoing, with safety data showing the drug was well tolerated. Arrowhead plans further studies and potential expansion into other diseases.

Cantor Fitzgerald reiterated an Overweight rating on Arrowhead Pharmaceuticals (ARWR) after positive Phase 1 data for ARO-MAPT showed a 70-75% reduction in cerebrospinal fluid tau. The company's market cap is $8.25B, with a 52.8% return over the past year. ARWR reported Q3 2026 revenue of $75.2M, beating estimates, but with a net loss of $1.36 per share. Analysts have price targets up to $126, with a consensus Strong Buy rating.

Chardan Capital reaffirmed its Buy rating on Arrowhead Pharma with a $115 price target, suggesting a 97% upside from the last close. The target is based on strong clinical data and growth potential from its RNAi therapies.

H.C. Wainwright reiterated a Buy rating and $120 price target for Arrowhead Pharmaceuticals (ARWR) after positive interim trial results for ARO-MAPT, showing up to 73% reduction in tau protein. ARWR shares are down 12% YTD but up 53% over the past year. The company reported Q3 2026 revenue of $75.2M, beating estimates, but with a larger net loss than expected. Analysts remain optimistic, with a consensus Strong Buy rating.

Arrowhead Pharmaceuticals (ARWR) reported that ARO-MAPT reduced total tau in CSF by up to 73% in healthy volunteers, marking the first clinical evidence of CNS target engagement by a brain shuttle-siRNA conjugate. The results suggest potential for RNAi therapies in Alzheimer's, but the optimal dose for clinical benefit remains unclear.